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The process of cancerogenesis is driven by the hierarchical
accumulation of genetic changes. So, beside the deregu-
lated expression of an oncogen, additional genetic defects
have to take place in order to transform a normal cell into
a tumor cell. In case of Burkitt's lymphoma, a c-myc-
driven haematological tumor, two predominant so called
2nd hits have been identified. First, loss-of-function
mutations in the p19-Mdm2-p53 tumor suppressor path-
way, and second, the over-expression of the anti-apoptotic
protein Bcl-2. So far it is not known whether these two dif-
ferent 2nd hits translate into cell-autonomous effects or
the ability of the immune system of recognizing and
destroying the tumor cells. Our studies revealed that nei-
ther over-expression of Bcl-2 nor loss-of-function muta-
tions in the p19-Mdm2-p53 tumor suppressor pathway
alters any analysed cell-autonomous effect significantly.
However, we could specify an impact of these additional
genetic lesions on the interaction between immune sys-
tem and tumor cells. We were able to show that tumor
cells over-expressing Bcl-2 can be eliminated by the
immune system more effectively than ones with p19-
Mdm2-p53 tumor suppressor pathway malfunctions.
These data are in line with the analysis regarding 2nd hits
of primary tumor samples obtained form an animal
model of Burkitt's lymphoma. This analysis showed a
clear survival advantage of mice suffering from tumors
over-expressing Bcl-2. Taken together, our studies provide
basic knowledge concerning the influence of the 2nd hit
on the interaction between immune system and tumor
cells, which might have prognostic value for immune
based cancer therapies.
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